Immunic's IMU-856 shows promise as Celiac Disease Awareness Month draws to a close

Proactive - Interviews for investors

Immunic Inc. Chief Scientific Officer Dr Hella Kohlhof talked with Proactive about the company's lead candidate IMU-856 and its potential to transform the treatment landscape for celiac disease. Kohlhof noted that celiac disease remains a chronic autoimmune condition with no approved drug therapies. While public awareness has increased, many misconceptions persist, particularly around gluten sensitivity being a lifestyle choice. According to Kohlhof, “Celiac disease is not just a dietary preference or a sensitivity... it’s really a chronic autoimmune condition.” IMU-856 is being developed to restore intestinal barrier function and improve gut wall architecture—an approach that directly targets the root cause of the disease rather than just its symptoms. In a recent Phase 1/1b trial, Immunic observed improvements in four key disease dimensions: histology, symptoms, biomarkers, and nutrient absorption. The therapy also demonstrated a favorable safety profile. Kohlhof highlighted that many patients still experience symptoms despite following a strict gluten-free diet, especially adults. She emphasized that IMU-856 could offer support for gut healing where dietary interventions fall short. The candidate may also have broader applications in inflammatory bowel conditions and even weight management, as recent data indicated a potential impact on GLP-1 levels. Visit Proactive’s YouTube channel for more interviews and updates. Don’t forget to like this video, subscribe to our channel, and enable notifications to stay informed. #CeliacDisease #ImmunicInc #IMU856 #GutHealth #AutoimmuneDisease #BiotechNews #ClinicalTrials #HealthcareInnovation #GLP1 #DrugDevelopment